RenovoRx, Inc. (RNXT)

NASDAQ: RNXT · IEX Real-Time Price · USD
0.620
+0.020 (3.28%)
At close: Dec 7, 2023, 3:32 PM
0.585
-0.035 (-5.61%)
After-hours: Dec 7, 2023, 7:19 PM EST
3.28%
Market Cap 5.99M
Revenue (ttm) n/a
Net Income (ttm) -9.16M
Shares Out 10.69M
EPS (ttm) -0.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 12,958
Open 0.560
Previous Close 0.600
Day's Range 0.560 - 0.640
52-Week Range 0.531 - 5.745
Beta -0.15
Analysts Buy
Price Target 13.00 (+1,997.11%)
Earnings Date Nov 14, 2023

About RNXT

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, Ca... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 26, 2021
Employees 10
Stock Exchange NASDAQ
Ticker Symbol RNXT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for RNXT stock is "Buy." The 12-month stock price forecast is $13.0, which is an increase of 1,997.11% from the latest price.

Price Target
$13.0
(1,997.11% upside)
Analyst Consensus: Buy
Stock Forecasts

News

RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced t...

21 days ago - Business Wire

RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced f...

23 days ago - Business Wire

RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced t...

2 months ago - Business Wire

RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced f...

4 months ago - Business Wire

RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced t...

4 months ago - Business Wire

RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform

LOS ALTOS, Calif. & SYDNEY--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd (“Imugene...

5 months ago - Business Wire

RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today presented n...

5 months ago - Business Wire

RenovoRx Appoints Margaret A. Tempero, M.D.

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced t...

6 months ago - Business Wire

RenovoRx Announces ROTH Capital Key Opinion Leader (KOL) Webcast on June 15

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced t...

6 months ago - Business Wire

RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical Trial

LOS ALTOS, Calif. & DALLAS--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today an...

6 months ago - Business Wire

RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced t...

7 months ago - Business Wire

RenovoRx to Present at the LD Micro Invitational XIII Conference

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of cancers, today announced that Shaun B...

7 months ago - Business Wire

RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of cancers, today announced financial re...

7 months ago - Business Wire

RenovoRx Sponsors Pancreatic Cancer Action Network's PurpleStride® Event

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced it joined Pan...

7 months ago - Business Wire

RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced that Shaun Ba...

7 months ago - Business Wire

RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on targeted drug-delivery with an initial application in locally ad...

8 months ago - Business Wire

RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced that Poster #...

8 months ago - Business Wire

RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced today that Le...

8 months ago - Business Wire

RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced that it has entered i...

9 months ago - Business Wire

RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced that it will ...

9 months ago - Business Wire

RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic Cancer

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced promisi...

9 months ago - Business Wire

RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today is reporting its ...

10 months ago - Business Wire

RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announces that Sh...

10 months ago - Business Wire

RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced that Shaun Bagai, Chief Executive O...

11 months ago - Business Wire

RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced initial results from a pharmacokine...

11 months ago - Business Wire